KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Income towards Parent Company (2016 - 2026)

Palvella Therapeutics has reported Income towards Parent Company over the past 10 years, most recently at -$11.9 million for Q3 2022.

  • Quarterly Income towards Parent Company rose 37.25% to -$11.9 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$31.6 million through Dec 2022, up 39.06% year-over-year, with the annual reading at $64000.0 for FY2025, N/A changed from the prior year.
  • Income towards Parent Company was -$11.9 million for Q3 2022 at Palvella Therapeutics, up from -$12.2 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$203000.0 in Q2 2018 and troughed at -$19.0 million in Q3 2021.
  • The 5-year median for Income towards Parent Company is -$10.3 million (2019), against an average of -$8.9 million.
  • Year-over-year, Income towards Parent Company soared 97.99% in 2018 and then tumbled 5692.12% in 2019.
  • A 5-year view of Income towards Parent Company shows it stood at -$11.7 million in 2018, then skyrocketed by 93.4% to -$771000.0 in 2019, then tumbled by 1508.69% to -$12.4 million in 2020, then grew by 11.27% to -$11.0 million in 2021, then decreased by 8.38% to -$11.9 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Income towards Parent Company are -$11.9 million (Q3 2022), -$12.2 million (Q2 2022), and -$7.5 million (Q1 2022).